603590.SH
Beijing Konruns Pharmaceutical Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 26.91
+1.55%Oct 21, 2026, 09:32 UTC
Kangchen Pharmaceutical plans to amend its articles of association and change its registered capital and total shares to 161.2571 million, subject to shareholder approval.
Source:Oct 21, 2026, 09:32 UTC
Kangchen Pharmaceutical announced plans to repurchase and cancel 15,000 restricted shares granted to an employee who left and became ineligible.
Source:Oct 16, 2026, 09:21 UTC
China’s National Medical Products Administration approved a clinical trial of Kangchen Pharmaceutical’s KC1086 in combination with fulvestrant for HR-positive/HER2-negative locally advanced or metastatic breast cancer.
Source:Oct 14, 2026, 10:51 UTC
Kangchen Pharmaceutical completed a share buyback of 1.9988 million shares, or 1.24% of its total share capital, for a total of RMB 78.4339 million.
Source:Aug 25, 2026, 10:32 UTC
Kangchen Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 95.7226 million yuan, up 5.14% year-on-year.
Source: